Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 27, 2013, Pages 11103-11108

  Tseng, Diane ^a,b   Volkmer, Jens Peter ^a,b   Willingham, Stephen B ^a,b   Contreras Trujillo, Humberto ^a,b   Fathman, John W ^a,b   Fernhoff, Nathaniel B ^a,b   Seita, Jun ^a,b   Inlay, Matthew A ^a,b   Weiskopf, Kipp ^a,b   Miyanishi, Masanori ^a,b   Weissman, Irving L ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER PHAGOCYTOSIS; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOTOXICITY; IMMUNE RESPONSE; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD47; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHAGOCYTOSIS; T-LYMPHOCYTES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; HARNESS;

EID: 84879733796     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1305569110     Document Type: Article

References (33)

1. Unanue ER (1972) The regulatory role of macrophages in antigenic stimulation. Adv Immunol 15:95-165.
2. Burgdorf S, Kautz A, Böhnert V, Knolle PA, Kurts C (2007) Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316(5824):612-616. (Pubitemid 46683149)
3. Bonifaz LC, et al. (2004) In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199(6):815-824. (Pubitemid 38375201)
4. Callahan MK, Wolchok JD, Allison JP (2010) Anti-CTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 37(5):473-484.
5. Majeti R, et al. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2):286-299.
6. Willingham SB, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109(17):6662-6667.
7. Brown EJ, Frazier WA (2001) Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11(3):130-135. (Pubitemid 32289443)
8. Oldenborg PA, et al. (2000) Role of CD47 as a marker of self on red blood cells. Science 288(5473):2051-2054.
9. Kharitonenkov A, et al. (1997) A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386(6621):181-186. (Pubitemid 27131446)
10. Fujioka Y, et al. (1996) A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol Cell Biol 16(12):6887-6899. (Pubitemid 26389748)
11. Timms JF, et al. (1998) Identification of major binding proteins and substrates for the SH2-containing protein tyrosine phosphatase SHP-1 in macrophages. Mol Cell Biol 18(7):3838-3850. (Pubitemid 28287907)
12. Tsai RK, Discher DE (2008) Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 180(5):989-1003. (Pubitemid 351398424)
13. Chao MP, et al. (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71(4):1374-1384.
14. Chao MP, et al. (2011) Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118(18):4890-4901.
15. Kim D, et al. (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26(12):2538-2545.
16. Edris B, et al. (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA 109(17):6656-6661.
17. Chao MP, et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142(5):699-713.
18. Chao MP, et al. (2010) Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2(63):63ra94.
19. Saito Y, et al. (2010) Regulation by SIRPá of dendritic cell homeostasis in lymphoid tissues. Blood 116(18):3517-3525.
20. Asano K, et al. (2011) CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 34(1):85-95.
21. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM (2001) Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 166(6):3717-3723. (Pubitemid 32224894)
22. Allan RS, et al. (2006) Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25(1):153-162. (Pubitemid 44066832)
23. Harbers SO, et al. (2007) Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 117(5):1361-1369. (Pubitemid 46718424)
24. Rafiq K, Bergtold A, Clynes R (2002) Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110(1):71-79. (Pubitemid 34743467)
25. Kong XN, et al. (2007) LPS-induced down-regulation of signal regulatory protein alpha contributes to innate immune activation in macrophages. J Exp Med 204(11):2719-2731.
26. Ramachandran IR, et al. (2011) The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function. J Immunol 186:3934-3945.
27. Basu S, Srivastava PK (1999) Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J ExpMed 189(5):797-802. (Pubitemid 29189684)
28. Nair S, et al. (1999) Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J Immunol 162(11):6426-6432. (Pubitemid 29309363)
29. Obeid M, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54-61. (Pubitemid 46067386)
30. Ticchioni M, et al. (2001) Integrin-associated protein (CD47/IAP) contributes to T cell arrest on inflammatory vascular endothelium under flow. FASEB J 15(2):341-350. (Pubitemid 32141426)
31. Reinhold MI, Lindberg FP, Kersh GJ, Allen PM, Brown EJ (1997) Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway. J Exp Med 185(1):1-11. (Pubitemid 27039436)
32. Waclavicek M, et al. (1997) T cell stimulation via CD47: Agonistic and antagonistic effects of CD47 monoclonal antibody 1/1A4. J Immunol 159(11):5345-5354. (Pubitemid 127470061)
33. Latour S, et al. (2001) Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: Down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J Immunol 167(5):2547-2554. (Pubitemid 32768881)